Vofatamab
Vofatamab (B-701) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control.
Product Specifications
CAS Number
1312305-12-6
Product Name Alternative
B-701; MFGR-1877S; RG-7444
UNSPSC
12352203
Target
FGFR
Type
Inhibitory Antibodies
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/vofatamab.html
Purity
99.9
Solubility
10 mM in DMSO
Smiles
[Vofatamab]
Molecular Weight
(146.44 kDa)
References & Citations
[1]Andrea Necchi, et al. Fierce-21: Phase II study of vofatmab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC) . Journal of Clinical Oncology 2019 37:7_suppl, 409-409.|[2]vofatamab
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
